Summary of results J: Relief of photophobia within two hours in placebo‐controlled studies
Route of administration	Dose (mg)	Number of		Number with outcome/total		Percent with outcome		Relative benefit (95% CI)	NNT (95% CI)
		Studies	Participants	Active	Placebo	Active	Placebo
In participants with moderate or severe baseline pain
Oral	25	3	411	97/240	35/171	40	20	1.8 (1.3 to 2.5)	5.0 (3.5 to 8.9)
Oral	50	6	1144	284/638	160/506	45	32	1.4 (1.2 to 1.7)	7.8 (5.4 to 14)
Oral	100	9	2494	834/1703	201/791	49	25	1.9 (1.6 to 2.1)	4.2 (3.7 to 5.1)
Subcutaneous	6	3	631	245/343	105/288	71	36	1.9 (1.6 to 2.2)	2.9 (2.4 to 3.6)
Intranasal	20	3	1021	314/643	89/378	49	24	2.1 (1.7 to 2.5)	4.0 (3.2 to 5.1)
In participants with mild baseline pain
Oral	50	3	483	125/237	44/246	53	18	3.0 (2.2 to 4.0)	2.9 (2.3 to 3.7)
Oral	100	3	475	131/229	44/246	57	18	3.2 (2.4 to 4.3)	2.5 (2.1 to 3.2)